OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
An updated patent review of BRD4 degraders
Zonghui Ma, Cun Zhang, Andrew A. Bolinger, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 929-951
Closed Access | Times Cited: 6
Zonghui Ma, Cun Zhang, Andrew A. Bolinger, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 929-951
Closed Access | Times Cited: 6
Showing 6 citing articles:
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
A patent review of von Hippel-Lindau (vhl)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)
Aina Urbina, Alex J. Hallatt, Jack Robertson, et al.
Expert Opinion on Therapeutic Patents (2025), pp. 1-42
Closed Access
Aina Urbina, Alex J. Hallatt, Jack Robertson, et al.
Expert Opinion on Therapeutic Patents (2025), pp. 1-42
Closed Access
Super-enhancers in tumors: unraveling recent advances in their role in Oncogenesis and the emergence of targeted therapies
Yu‐meng Ji, Baixue Li, Rongjin Lin, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Yu‐meng Ji, Baixue Li, Rongjin Lin, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease
Zonghui Ma, Steven McAninch, Zhiqing Liu, et al.
ACS Pharmacology & Translational Science (2025)
Closed Access
Zonghui Ma, Steven McAninch, Zhiqing Liu, et al.
ACS Pharmacology & Translational Science (2025)
Closed Access
BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease
Zonghui Ma, Andrew A. Bolinger, Irina V. Pinchuk, et al.
Advances in pharmacology (2024), pp. 203-236
Closed Access | Times Cited: 1
Zonghui Ma, Andrew A. Bolinger, Irina V. Pinchuk, et al.
Advances in pharmacology (2024), pp. 203-236
Closed Access | Times Cited: 1
Recent Advances in Developing Targeted Protein Degraders
Binbin Cheng, Hongqiao Li, Xiaopeng Peng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117212-117212
Closed Access
Binbin Cheng, Hongqiao Li, Xiaopeng Peng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117212-117212
Closed Access
